Loading...
•
Mar 31, 2024
Nkarta Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
Nkarta reported a cash balance of $450.0 million as of March 31, 2024, bolstered by a recent $240.1 million offering, which is expected to fund operations into late 2027. The company's net loss for the quarter was $29.5 million, or $0.58 per share.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024
Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments
Strong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027
Nkarta expects to announce preliminary data from the NKX019 compressed dosing cohort in mid-2024.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...